ELIXIR SOFTWARE LTD

Risk Rating: LOW The company demonstrates a strong and improving net asset position, healthy liquidity, and consistent growth in retained earnings over a sustained period. Regulatory compliance appears robust with no overdue filings. The primary risks are operational and relate to the composition of balance sheet items rather than existential threats to the business.

Key Concerns: - Rising "Other Creditors": Current liabilities include £510,270 in "other creditors," a significant increase from £365,965 the prior year. This now represents the vast majority of total liabilities. Without further detail, it is unclear if this represents deferred income, director loans, or accrued expenses, but the scale and growth warrant scrutiny. - Concentration in "Other Debtors": Current assets include £494,021 in "other debtors" (up from £344,096), which alongside trade debtors (£505,189) makes up the bulk of current assets. If these "other debtors" are not readily realizable, the true liquidity position could be weaker than the cash figures suggest. - Declining Cash Position: While cash at bank remains robust at £497,716, this represents a noticeable drop from £650,372 in 2023 and £855,030 in 2022. This decline coincides with the increase in debtors and creditors, suggesting potential cash flow timing issues or changes in payment terms.

Positive Indicators: - Consistent Capital Growth: The company has demonstrated unbroken growth in net assets and shareholders' funds over the last decade, moving from £13,062 in 2014 to £912,818 in 2024. This indicates a sustainable, profitable business model. - Strong Liquidity Buffer: Net current assets stand at £897,003 against current liabilities of £609,103. The company holds substantial cash reserves and appears well-positioned to meet its short-term obligations comfortably. - Regulatory and Filing Compliance: The company is up to date with its accounts and confirmation statements, with no filings overdue. It appropriately utilizes the small companies' regime, and the accounts are authorized in a timely manner.

Due Diligence Notes: - Breakdown of Debtors and Creditors: An investor should request a detailed breakdown of the "other debtors" and "other creditors" to understand the nature of these balances, their collectability, and the terms attached to them. - Profitability vs. Cash Conversion: The Profit and Loss reserve increased by approximately £29,436, while trade debtors increased significantly. It would be prudent to investigate the company's EBITDA margin, revenue recognition policies, and how effectively it converts its growing debtor book into cash. - Revenue Concentration: Given the specialized nature of the business (iTraX visualized workflow software for Drug Discovery), it is important to establish the customer concentration risk—specifically, how many clients account for the £505,189 in trade debtors and what the pipeline for the software looks like. - Board Composition and PSC: There are five directors and three PSCs. It would be beneficial to understand the relationship between the directors and the PSCs, their working dynamics, and if the "other creditors" include any director loans or related party transactions.